Real-World Evidence and Market Assessment Studies
Understand standard of care and patient outcomes to support the design of clinical trials and eligible patient populations.
Support reimbursement decision and HEOR studies by better understanding healthcare resource use.
Enhance drug development strategies across the entire drug life cycle, by better understanding current and future patient population sizes
Form the basis of a robust and defensible Orphan Drug Designation application by analysing data from both primary and secondary care records
Without real-world evidence (RWE), pharmaceutical companies risk missing vital insights that drive successful decision-making. Clinical trials alone don’t capture the diverse patient populations and real-world scenarios crucial for understanding true drug performance.
Neglecting RWE can lead to misguided strategies, ineffective treatments, and suboptimal patient outcomes. This oversight not only hampers patient care but also poses regulatory challenges and diminishes market competitiveness.
Embracing RWE empowers pharma companies to make informed, impactful decisions, ensuring treatments are effective across all patient groups and enhancing their position in the market.
how it works
Our expert team works closely with you to scope out your requirements and design an RWE or market assessment study. With decades of experience working with hospitals and healthcare data, we can ensure these studies address your evidence gaps and commercial insight needs.
Using our inhouse RWE datasets and network of data partners, we can provide rich insights to inform decision-making all the way from clinical trial design to label extensions and safety studies.
Our suite of epidemiological forecasting models and techniques gives us the capability to deliver reliable and defensible forecasts for even the rarest of diseases.
Actionable evidence-based insights that service the needs of the pharmaceutical industry throughout all development phases.
Expert teams with many years of experience in RWE, epidemiology and data science.
Extensive network of data partners and clinical sites, as well as inhouse real-world datasets for rapid insight generation.
Case studies
Increasing diagnosis rates and time-to-diagnosis for a rare liver disease
Find out more about Increasing diagnosis rates and time-to-diagnosis for a rare liver disease